xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT05962801</url>
    </required_header>
    <id_info>
      <org_study_id>176/30-11-2022</org_study_id>
      <nct_id>NCT05962801</nct_id>
    </id_info>
    <brief_title>Use of Dual-light Photodynamic Therapy as an Adjunct to Periodontal Treatment in Smokers</brief_title>
    <official_title>Regular Home Use of Dual-light Photodynamic Therapy as an Adjunct to Non-surgical Periodontal Treatment in Smokers</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>Aristotle University Of Thessaloniki</agency>
        <agency_class>Other</agency_class>
      </lead_sponsor>
      <collaborator>
        <agency>University of Helsinki</agency>
        <agency_class>Other</agency_class>
      </collaborator>
    </sponsors>
    <source>Aristotle University Of Thessaloniki</source>
    <oversight_info>
      <has_dmc>No</has_dmc>
      <is_fda_regulated_drug>No</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        The goal of this controlled clinical trial is to investigate the impact of regular home use&#xD;
        of Lumoral device as an adjunct treatment compared to non-surgical periodontitis treatment&#xD;
        (NSPT) alone on biofilm removal and host response in Stage III and Grade C smoking&#xD;
        periodontitis patients at 6 months.The main question aims to answer is:&#xD;
  &#xD;
        • Does regular use of dual-light photodynamic therapy benefit NSPT in Stage III and Grade C&#xD;
        smoking periodontitis patients?&#xD;
  &#xD;
        30 participants will be asked to use Lumoral device every night before performing oral&#xD;
        hygiene for 10 minutes, while the other 30 patients will be asked to perform only oral&#xD;
        hygiene. Both of these groups will receive NSPT and will be followed for 6 months from&#xD;
        baseline.&#xD;
      </textblock>
    </brief_summary>
    <detailed_description>
      <textblock>
        Objectives: To investigate the impact of regular home use of Lumoral device as an adjunct&#xD;
        treatment compared to NSPT alone on biofilm removal and host response in Stage III and Grade&#xD;
        C smoking periodontitis patients at 6 months.&#xD;
  &#xD;
        Methodology: Randomized study; randomization method: www.randomizer.org&#xD;
  &#xD;
        Sample size: 60 subjects, 30 subjects in the study group, and 30 in the control group. The&#xD;
        subjects have a referral to visit a specialist dentist/ periodontist.&#xD;
  &#xD;
        Main criteria for inclusion: Periodontal disease Stage III and Grade C with at least 6 sites&#xD;
        with probing depth (PD) and clinical attachment loss (CAL) ≥5 mm and bleeding on probing&#xD;
        (BOP) ≥15 teeth, aged ≥35, smokers smoking ≥10 cigarettes per day, presence of ≥20 teeth,&#xD;
        agreement to participate in the study and a written consent form signed.&#xD;
  &#xD;
        Main criteria for exclusion: Presence of any physical limitation or restriction for Lumoral&#xD;
        use, need for prophylactic antimicrobial coverage, scaling and root planing performed during&#xD;
        the previous 6 months, non-smoking status or smoking ≤ 10 cigarettes per day, antimicrobial&#xD;
        therapy in the previous 6 months, immune modifying conditions/ diseases (e.g., diabetes&#xD;
        mellitus, rheumatoid arthritis, and osteoporosis), long-term use of medication that could&#xD;
        interfere with the periodontal response (e.g., bisphosphonates), pregnancy or lactation.&#xD;
  &#xD;
        Assessments:&#xD;
  &#xD;
        Primary outcome: Differences in bleeding on probing index (BOP) between test and control&#xD;
        group.&#xD;
  &#xD;
        Secondary outcome: Differences in the number of reduced deep pockets (i.e. PD≤ 4mm, no BOP),&#xD;
        pocket depth (PD), clinical attachment level (CAL), Turetsky Modified Quigley-Hein Plaque&#xD;
        Index (TMQHPI), salivary levels of MMP-8, Oral Health Quality of Life (OHQL) questionnaire&#xD;
        and need for optional SRP.&#xD;
  &#xD;
        Statistical methods: Wilcoxon test, Mann-Whitney U-test, Fisher's test, Pearson's correlation&#xD;
        test&#xD;
      </textblock>
    </detailed_description>
    <overall_status>Recruiting</overall_status>
    <start_date type="Actual">January 23, 2023</start_date>
    <completion_date type="Anticipated">September 1, 2024</completion_date>
    <primary_completion_date type="Anticipated">June 1, 2024</primary_completion_date>
    <phase>N/A</phase>
    <study_type>Interventional</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <allocation>Randomized</allocation>
      <intervention_model>Parallel Assignment</intervention_model>
      <intervention_model_description>Randomized, controlled clinical trial</intervention_model_description>
      <primary_purpose>Treatment</primary_purpose>
      <masking>None (Open Label)</masking>
    </study_design_info>
    <primary_outcome>
      <measure>Changes in bleeding on probing (BOP)</measure>
      <time_frame>baseline, 2 weeks, 2 months, 6 months</time_frame>
      <description>Changes in the presence of bleeding when probing at 6 sites per tooth. It is evaluated dichotomously.</description>
    </primary_outcome>
    <secondary_outcome>
      <measure>Changes of pocket depths</measure>
      <time_frame>baseline, 2 months, 6 months</time_frame>
      <description>Changes in measurement in millimeters of the depth from the gingival margin to the epithelial attachment in unhealthy gingival tissue at 6 sites per tooth</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Changes in clinical attachment level</measure>
      <time_frame>baseline, 2 months, 6 months</time_frame>
      <description>Changes in measurement of the position of the gingival margin in relation to the cemento-enamel junction (CEJ) at 6 sites per tooth</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Difference in the number of &quot;closed&quot; pockets</measure>
      <time_frame>baseline, 2 months, 6 months</time_frame>
      <description>Differences in the number of pockets with depth≤ 4mm and no BOP between the test and the control group</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>a-MMP8 saliva concentration</measure>
      <time_frame>baseline, 2 weeks, 2 months, 6 months</time_frame>
      <description>Periosafe chair-side tests and the ORALyzer (an advanced lateral flow (aLF) reader) are utilized in order to quantify active MMP-8 in subjects' saliva</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Changes in Turetsky Modified Quigley-Hein Plaque Index (TMQHPI)</measure>
      <time_frame>baseline, 2 weeks, 2 months, 6 months</time_frame>
      <description>Changes in TMQHPI in buccal surfaces of the upper and lower anterior teeth</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Oral health-related quality of life questionnaire (OHQL)</measure>
      <time_frame>2 months, 6 months</time_frame>
      <description>OHQL includes the following questions:&#xD;
  Did you use Lumoral® as instructed to you?&#xD;
  Did you find Lumoral® easy to use?&#xD;
  Did you feel any discomfort when using Lumoral®?&#xD;
  Did you discontinue the use of Lumoral® due to this discomfort?&#xD;
  Did Lumoral® helped you perform oral hygiene?&#xD;
  Has bad breath been decreased?&#xD;
  Has bleeding of the gums been decreased?&#xD;
  Would you recommend Lumoral®?&#xD;
  Would you buy Lumoral® if its cost was about 200 €?</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Changes in the presence of periopathogens in the deepest pocket</measure>
      <time_frame>baseline, 2 months, 6 months</time_frame>
      <description>Subgingival plaque sample is collected from the deepest pocket of each patient and the presence of periopathogens is detected</description>
    </secondary_outcome>
    <number_of_arms>2</number_of_arms>
    <enrollment type="Anticipated">60</enrollment>
    <condition>Periodontitis</condition>
    <condition>Dual- Light Photodynamic Therapy</condition>
    <condition>Smoking, Cigarette</condition>
    <condition>Non-surgical Periodontal Therapy</condition>
    <arm_group>
      <arm_group_label>Lumoral users</arm_group_label>
      <arm_group_type>Active Comparator</arm_group_type>
      <description>Use of Lumoral device and Lumorinse mouthwash once per day for 6 months and performance of oral hygiene twice per day for 6 months.</description>
    </arm_group>
    <arm_group>
      <arm_group_label>Lumoral non-users</arm_group_label>
      <arm_group_type>No Intervention</arm_group_type>
      <description>No use of Lumoral device and Lumorinse mouthwash. Performance of oral hygiene twice per day for 6 months.</description>
    </arm_group>
    <intervention>
      <intervention_type>Device</intervention_type>
      <intervention_name>Lumoral device, Lumorinse</intervention_name>
      <description>Regular use of dual-light photodynamic therapy at home</description>
      <arm_group_label>Lumoral users</arm_group_label>
    </intervention>
    <eligibility>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
            -  Periodontal disease Stage III and Grade C with at least 6 sites with probing depth&#xD;
               (PD) and clinical attachment loss (CAL) ≥5 mm and bleeding on probing (BoP) ≥15 teeth&#xD;
  &#xD;
            -  aged ≥35&#xD;
  &#xD;
            -  Smokers smoking ≥10 cigarettes per day&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
            -  Patients allergic to indocyanine&#xD;
  &#xD;
            -  Patients with active carious lesions&#xD;
  &#xD;
            -  Need for prophylactic antimicrobial coverage&#xD;
  &#xD;
            -  Scaling and root planing in the previous 6 months&#xD;
  &#xD;
            -  Non-smoking status or smoking less than 10 cigarettes per day&#xD;
  &#xD;
            -  Antimicrobial therapy in the previous 6 months&#xD;
  &#xD;
            -  Immunomodifying conditions/ diseases (e.g. diabetes mellitus, rheumatoid arthritis,&#xD;
               osteoporosis)&#xD;
  &#xD;
            -  Long-term use of medication that could interfere with periodontal response (e.g.&#xD;
               biphosphonates)&#xD;
  &#xD;
            -  Pregnancy or lactation&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>35 Years</minimum_age>
      <maximum_age>N/A</maximum_age>
      <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
    </eligibility>
    <overall_official>
      <last_name>Dimitra Sakellari, Professor</last_name>
      <role>Study Director</role>
      <affiliation>Aristotle University Of Thessaloniki</affiliation>
    </overall_official>
    <overall_contact>
      <last_name>Chrysoula Vakaki, Postgraduate</last_name>
      <phone>0030 6979766034</phone>
      <email>vakakichri@gmail.com</email>
    </overall_contact>
    <overall_contact_backup>
      <last_name>Dimitra Sakellari, Professor</last_name>
      <phone>0030 6945777768</phone>
      <email>dimisak@gmail.com</email>
    </overall_contact_backup>
    <location>
      <facility>
        <name>Dental School of Aristotle University of Thessaloniki</name>
        <address>
          <city>Thessaloníki</city>
          <zip>54124</zip>
          <country>Greece</country>
        </address>
      </facility>
      <status>Recruiting</status>
      <contact>
        <last_name>Chrysoula Vakaki, Postgraduate</last_name>
        <phone>0030 6979766034</phone>
        <email>vakakichri@gmail.com</email>
      </contact>
      <contact_backup>
        <last_name>Dimitra Sakellari, Professor</last_name>
        <phone>0030 6945777768</phone>
        <email>dimisak@dent.auth.gr</email>
      </contact_backup>
    </location>
    <location_countries>
      <country>Greece</country>
    </location_countries>
    <reference>
      <citation>AlSarhan MA, Altammami MA, Alaqeely RS, AlEbdi A, Jasser RA, Otaibi DA, Oraini SA, Habib SR, Alqahtani L, Alduhaymi IS, Alrabiah DK, Alaradi M, Alyamani EJ. Short-term improvement of clinical parameters and microbial diversity in periodontitis patients following Indocyanine green-based antimicrobial photodynamic therapy: A randomized single-blind split-mouth cohort. Photodiagnosis Photodyn Ther. 2021 Sep;35:102349. doi: 10.1016/j.pdpdt.2021.102349. Epub 2021 May 24.</citation>
      <PMID>34033939</PMID>
    </reference>
    <reference>
      <citation>Lahteenmaki H, Patila T, Raisanen IT, Kankuri E, Tervahartiala T, Sorsa T. Repeated Home-Applied Dual-Light Antibacterial Photodynamic Therapy Can Reduce Plaque Burden, Inflammation, and aMMP-8 in Peri-Implant Disease-A Pilot Study. Curr Issues Mol Biol. 2022 Mar 8;44(3):1273-1283. doi: 10.3390/cimb44030085.</citation>
      <PMID>35723308</PMID>
    </reference>
    <reference>
      <citation>Trujiilo K, Raisanen IT, Sorsa T, Patila T. Repeated Daily Use of Dual-Light Antibacterial Photodynamic Therapy in Periodontal Disease-A Case Report. Dent J (Basel). 2022 Sep 1;10(9):163. doi: 10.3390/dj10090163.</citation>
      <PMID>36135158</PMID>
    </reference>
    <reference>
      <citation>Alassiri S, Parnanen P, Rathnayake N, Johannsen G, Heikkinen AM, Lazzara R, van der Schoor P, van der Schoor JG, Tervahartiala T, Gieselmann D, Sorsa T. The Ability of Quantitative, Specific, and Sensitive Point-of-Care/Chair-Side Oral Fluid Immunotests for aMMP-8 to Detect Periodontal and Peri-Implant Diseases. Dis Markers. 2018 Aug 5;2018:1306396. doi: 10.1155/2018/1306396. eCollection 2018.</citation>
      <PMID>30154936</PMID>
    </reference>
    <reference>
      <citation>Jansson H, Wahlin A, Johansson V, Akerman S, Lundegren N, Isberg PE, Norderyd O. Impact of periodontal disease experience on oral health-related quality of life. J Periodontol. 2014 Mar;85(3):438-45. doi: 10.1902/jop.2013.130188. Epub 2013 Jul 29.</citation>
      <PMID>23895254</PMID>
    </reference>
    <reference>
      <citation>Turesky S, Gilmore ND, Glickman I. Reduced plaque formation by the chloromethyl analogue of victamine C. J Periodontol. 1970 Jan;41(1):41-3. doi: 10.1902/jop.1970.41.41.41. No abstract available.</citation>
      <PMID>5264376</PMID>
    </reference>
    <reference>
      <citation>Chambrone L, Wang HL, Romanos GE. Antimicrobial photodynamic therapy for the treatment of periodontitis and peri-implantitis: An American Academy of Periodontology best evidence review. J Periodontol. 2018 Jul;89(7):783-803. doi: 10.1902/jop.2017.170172.</citation>
      <PMID>30133749</PMID>
    </reference>
    <reference>
      <citation>Pakarinen S, Saarela RKT, Valimaa H, Heikkinen AM, Kankuri E, Noponen M, Alapulli H, Tervahartiala T, Raisanen IT, Sorsa T, Patila T. Home-Applied Dual-Light Photodynamic Therapy in the Treatment of Stable Chronic Periodontitis (HOPE-CP)-Three-Month Interim Results. Dent J (Basel). 2022 Nov 2;10(11):206. doi: 10.3390/dj10110206.</citation>
      <PMID>36354651</PMID>
    </reference>
    <verification_date>July 2023</verification_date>
    <study_first_submitted>July 19, 2023</study_first_submitted>
    <study_first_submitted_qc>July 19, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">July 27, 2023</study_first_posted>
    <last_update_submitted>July 19, 2023</last_update_submitted>
    <last_update_submitted_qc>July 19, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">July 27, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Principal Investigator</responsible_party_type>
      <investigator_affiliation>Aristotle University Of Thessaloniki</investigator_affiliation>
      <investigator_full_name>Dimitra Sakellari</investigator_full_name>
      <investigator_title>Professor</investigator_title>
    </responsible_party>
    <keyword>periodontitis</keyword>
    <keyword>periodontal diseases</keyword>
    <keyword>photodynamic therapy</keyword>
    <keyword>photothermal therapy</keyword>
    <keyword>smoking</keyword>
    <keyword>non-surgical periodontitis therapy</keyword>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Periodontitis</mesh_term>
    </condition_browse>
    <patient_data>
      <sharing_ipd>No</sharing_ipd>
      <ipd_description>Patients' data will be recorded in the electronic patients' database of the Dental School of Aristotle University of Thessaloniki and only the researchers of this study will have access to them.</ipd_description>
    </patient_data>
    <provided_document_section>
      <provided_document>
        <document_type>Study Protocol and Statistical Analysis Plan</document_type>
        <document_has_protocol>Yes</document_has_protocol>
        <document_has_icf>No</document_has_icf>
        <document_has_sap>Yes</document_has_sap>
        <document_date>October 16, 2022</document_date>
        <document_url>https://ClinicalTrials.gov/ProvidedDocs/01/NCT05962801/Prot_SAP_000.pdf</document_url>
      </provided_document>
    </provided_document_section>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT05962801
  org study id: 176/30-11-2022
  nct id: NCT05962801
  lead sponsor: 
  collaborator: 
  has dmc: No
  is fda regulated drug: No
  is fda regulated device: No
  The goal of this controlled clinical trial is to investigate the impact of regular home use
        of Lumoral device as an adjunct treatment compared to non-surgical periodontitis treatment
        (NSPT) alone on biofilm removal and host response in Stage III and Grade C smoking
        periodontitis patients at 6 months.The main question aims to answer is:
  
        • Does regular use of dual-light photodynamic therapy benefit NSPT in Stage III and Grade C
        smoking periodontitis patients?
  
        30 participants will be asked to use Lumoral device every night before performing oral
        hygiene for 10 minutes, while the other 30 patients will be asked to perform only oral
        hygiene. Both of these groups will receive NSPT and will be followed for 6 months from
        baseline.
  Objectives: To investigate the impact of regular home use of Lumoral device as an adjunct
        treatment compared to NSPT alone on biofilm removal and host response in Stage III and Grade
        C smoking periodontitis patients at 6 months.
  
        Methodology: Randomized study; randomization method: www.randomizer.org
  
        Sample size: 60 subjects, 30 subjects in the study group, and 30 in the control group. The
        subjects have a referral to visit a specialist dentist/ periodontist.
  
        Main criteria for inclusion: Periodontal disease Stage III and Grade C with at least 6 sites
        with probing depth (PD) and clinical attachment loss (CAL) ≥5 mm and bleeding on probing
        (BOP) ≥15 teeth, aged ≥35, smokers smoking ≥10 cigarettes per day, presence of ≥20 teeth,
        agreement to participate in the study and a written consent form signed.
  
        Main criteria for exclusion: Presence of any physical limitation or restriction for Lumoral
        use, need for prophylactic antimicrobial coverage, scaling and root planing performed during
        the previous 6 months, non-smoking status or smoking ≤ 10 cigarettes per day, antimicrobial
        therapy in the previous 6 months, immune modifying conditions/ diseases (e.g., diabetes
        mellitus, rheumatoid arthritis, and osteoporosis), long-term use of medication that could
        interfere with the periodontal response (e.g., bisphosphonates), pregnancy or lactation.
  
        Assessments:
  
        Primary outcome: Differences in bleeding on probing index (BOP) between test and control
        group.
  
        Secondary outcome: Differences in the number of reduced deep pockets (i.e. PD≤ 4mm, no BOP),
        pocket depth (PD), clinical attachment level (CAL), Turetsky Modified Quigley-Hein Plaque
        Index (TMQHPI), salivary levels of MMP-8, Oral Health Quality of Life (OHQL) questionnaire
        and need for optional SRP.
  
        Statistical methods: Wilcoxon test, Mann-Whitney U-test, Fisher's test, Pearson's correlation
        test
  allocation: Randomized
  intervention model: Parallel Assignment
  intervention model description: Randomized, controlled clinical trial
  primary purpose: Treatment
  masking: None (Open Label)
  measure: Changes in bleeding on probing (BOP)
  time frame: baseline, 2 weeks, 2 months, 6 months
  description: Changes in the presence of bleeding when probing at 6 sites per tooth. It is evaluated dichotomously.
  measure: Changes of pocket depths
  time frame: baseline, 2 months, 6 months
  description: Changes in measurement in millimeters of the depth from the gingival margin to the epithelial attachment in unhealthy gingival tissue at 6 sites per tooth
  measure: Changes in clinical attachment level
  time frame: baseline, 2 months, 6 months
  description: Changes in measurement of the position of the gingival margin in relation to the cemento-enamel junction (CEJ) at 6 sites per tooth
  measure: Difference in the number of "closed" pockets
  time frame: baseline, 2 months, 6 months
  description: Differences in the number of pockets with depth≤ 4mm and no BOP between the test and the control group
  measure: a-MMP8 saliva concentration
  time frame: baseline, 2 weeks, 2 months, 6 months
  description: Periosafe chair-side tests and the ORALyzer (an advanced lateral flow (aLF) reader) are utilized in order to quantify active MMP-8 in subjects' saliva
  measure: Changes in Turetsky Modified Quigley-Hein Plaque Index (TMQHPI)
  time frame: baseline, 2 weeks, 2 months, 6 months
  description: Changes in TMQHPI in buccal surfaces of the upper and lower anterior teeth
  measure: Oral health-related quality of life questionnaire (OHQL)
  time frame: 2 months, 6 months
  description: OHQL includes the following questions:
  Did you use Lumoral® as instructed to you?
  Did you find Lumoral® easy to use?
  Did you feel any discomfort when using Lumoral®?
  Did you discontinue the use of Lumoral® due to this discomfort?
  Did Lumoral® helped you perform oral hygiene?
  Has bad breath been decreased?
  Has bleeding of the gums been decreased?
  Would you recommend Lumoral®?
  Would you buy Lumoral® if its cost was about 200 €?
  measure: Changes in the presence of periopathogens in the deepest pocket
  time frame: baseline, 2 months, 6 months
  description: Subgingival plaque sample is collected from the deepest pocket of each patient and the presence of periopathogens is detected
  arm group label: Lumoral users
  arm group type: Active Comparator
  description: Use of Lumoral device and Lumorinse mouthwash once per day for 6 months and performance of oral hygiene twice per day for 6 months.
  arm group label: Lumoral non-users
  arm group type: No Intervention
  description: No use of Lumoral device and Lumorinse mouthwash. Performance of oral hygiene twice per day for 6 months.
  intervention type: Device
  intervention name: Lumoral device, Lumorinse
  description: Regular use of dual-light photodynamic therapy at home
  arm group label: Lumoral users
  criteria: 
  gender: All
  minimum age: 35 Years
  maximum age: N/A
  healthy volunteers: Accepts Healthy Volunteers
  last name: Dimitra Sakellari, Professor
  role: Study Director
  affiliation: Aristotle University Of Thessaloniki
  last name: Chrysoula Vakaki, Postgraduate
  phone: 0030 6979766034
  email: vakakichri@gmail.com
  last name: Dimitra Sakellari, Professor
  phone: 0030 6945777768
  email: dimisak@gmail.com
  facility: 
  status: Recruiting
  contact: 
  contact backup: 
  country: Greece
  citation: AlSarhan MA, Altammami MA, Alaqeely RS, AlEbdi A, Jasser RA, Otaibi DA, Oraini SA, Habib SR, Alqahtani L, Alduhaymi IS, Alrabiah DK, Alaradi M, Alyamani EJ. Short-term improvement of clinical parameters and microbial diversity in periodontitis patients following Indocyanine green-based antimicrobial photodynamic therapy: A randomized single-blind split-mouth cohort. Photodiagnosis Photodyn Ther. 2021 Sep;35:102349. doi: 10.1016/j.pdpdt.2021.102349. Epub 2021 May 24.
  PMID: 34033939
  citation: Lahteenmaki H, Patila T, Raisanen IT, Kankuri E, Tervahartiala T, Sorsa T. Repeated Home-Applied Dual-Light Antibacterial Photodynamic Therapy Can Reduce Plaque Burden, Inflammation, and aMMP-8 in Peri-Implant Disease-A Pilot Study. Curr Issues Mol Biol. 2022 Mar 8;44(3):1273-1283. doi: 10.3390/cimb44030085.
  PMID: 35723308
  citation: Trujiilo K, Raisanen IT, Sorsa T, Patila T. Repeated Daily Use of Dual-Light Antibacterial Photodynamic Therapy in Periodontal Disease-A Case Report. Dent J (Basel). 2022 Sep 1;10(9):163. doi: 10.3390/dj10090163.
  PMID: 36135158
  citation: Alassiri S, Parnanen P, Rathnayake N, Johannsen G, Heikkinen AM, Lazzara R, van der Schoor P, van der Schoor JG, Tervahartiala T, Gieselmann D, Sorsa T. The Ability of Quantitative, Specific, and Sensitive Point-of-Care/Chair-Side Oral Fluid Immunotests for aMMP-8 to Detect Periodontal and Peri-Implant Diseases. Dis Markers. 2018 Aug 5;2018:1306396. doi: 10.1155/2018/1306396. eCollection 2018.
  PMID: 30154936
  citation: Jansson H, Wahlin A, Johansson V, Akerman S, Lundegren N, Isberg PE, Norderyd O. Impact of periodontal disease experience on oral health-related quality of life. J Periodontol. 2014 Mar;85(3):438-45. doi: 10.1902/jop.2013.130188. Epub 2013 Jul 29.
  PMID: 23895254
  citation: Turesky S, Gilmore ND, Glickman I. Reduced plaque formation by the chloromethyl analogue of victamine C. J Periodontol. 1970 Jan;41(1):41-3. doi: 10.1902/jop.1970.41.41.41. No abstract available.
  PMID: 5264376
  citation: Chambrone L, Wang HL, Romanos GE. Antimicrobial photodynamic therapy for the treatment of periodontitis and peri-implantitis: An American Academy of Periodontology best evidence review. J Periodontol. 2018 Jul;89(7):783-803. doi: 10.1902/jop.2017.170172.
  PMID: 30133749
  citation: Pakarinen S, Saarela RKT, Valimaa H, Heikkinen AM, Kankuri E, Noponen M, Alapulli H, Tervahartiala T, Raisanen IT, Sorsa T, Patila T. Home-Applied Dual-Light Photodynamic Therapy in the Treatment of Stable Chronic Periodontitis (HOPE-CP)-Three-Month Interim Results. Dent J (Basel). 2022 Nov 2;10(11):206. doi: 10.3390/dj10110206.
  PMID: 36354651
  responsible party type: Principal Investigator
  investigator affiliation: Aristotle University Of Thessaloniki
  investigator full name: Dimitra Sakellari
  investigator title: Professor
  mesh term: Periodontitis
  sharing ipd: No
  ipd description: Patients' data will be recorded in the electronic patients' database of the Dental School of Aristotle University of Thessaloniki and only the researchers of this study will have access to them.
  provided document: 